Legend Biotech Results Presentation Deck

11 2023 3Q and YTD Financial Summary ($MM) Cash and Cash Equivalents, Time Deposits, and Short-Term Investments ($MM) License revenue Collaboration revenue Other revenue Total revenue Collaboration cost of revenue Research and development expenses Administrative expenses Selling and distribution expenses LOSS FOR THE PERIOD September 30, 2023 3Q 2023 20 76 0 96 -43 -96 -28 -21 -62 1,428 3Q 2022 0 27 0 27 -25 -105 -23 -19 -85 Y/Y change 178% -69% 251% 71% -8% 21% June 30, 2023 12% -27% This presentation is for investor relations purposes only - Not for product promotional purposes 1,519 YTD 2023 YTD 2022 35 170 0 206 -112 -277 -78 -60 -373 50 39 0 89 March 31, 2023 -42 -255 -54 -68 -310 854 Y/Y change -30% 334% 1% 130% 164% 8% 45% -11% 20% Cash and cash equivalents, time deposits, and short- term investments totaling approximately $1.4B as of September 30, 2023, which we believe will fund operating and capital expenditures through 2025. LEGEND BIOTECH

View entire presentation